ACURATE neo2: jack of all trades or master of none?

Transcatheter aortic valve implantation (TAVI) is now indicated across all risk categories of patients with symptomatic severe aortic stenosis and has been proposed as a first-line option for the majority of patients ≥75 years old. The former discussion of whether a patient should undergo surgical aortic valve replacement (SAVR) or TAVI is shifting from patient age and surgical risk to life expectancy and the associated lifetime management of aortic stenosis for an individual patient1.

As indications for TAVI expand to include younger and healthier patients who are expected to outlive their initial transcatheter heart valve (THV), understanding ...